Tafasitamab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB15044 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 10 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | drug-induced osteoporosis | KG + DL |
| 2 | severe nonproliferative diabetic retinopathy | KG + DL |
| 3 | diabetic retinopathy | KG + DL |
| 4 | HER2 positive breast carcinoma | KG + DL |
| 5 | psoriasis | KG + DL |
| 6 | normal breast-like subtype of breast carcinoma | KG + DL |
| 7 | progesterone-receptor positive breast cancer | KG + DL |
| 8 | breast tumor luminal A or B | KG + DL |
| 9 | progesterone-receptor negative breast cancer | KG + DL |
| 10 | pityriasis lichenoides | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.